Advertisement

Reactions Weekly

, Volume 1730, Issue 1, pp 60–60 | Cite as

Atezolizumab/nivolumab

Various toxicities: 19 case reports
Case report
  • 10 Downloads

Reference

  1. Tachihara M, et al. Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer 18: 946, No. 1, 3 Oct 2018. Available from: URL: http://doi.org/10.1186/s12885-018-4819-2 - Japan

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations